62.5 mg & 125 mg
Antihypertensive (Pulmonary) / Vasodilator antihypertensive
Bosentan is indicated for Pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise ability and to decrease clinical worsening, and Systemic sclerosis with ongoing digital ulcer disease.
Sentobiox is indicated for Hypertension and Chronic thromboembolic pulmonary hypertension, as well.
Dosage and Administration:
Pulmonary arterial hypertension: initially 62.5 mg twice daily, increased after 4 weeks to 125 mg twice daily, max. 250 mg twice daily.
Systemic sclerosis with ongoing digital ulcer disease: initially 62.5 mg twice daily, increased after 4 weeks to 125 mg twice daily.
Coution is advised for each following situations:
Pre-existing hepatic and renal impairment, Fluid retention, Pulmonary edema, Decreased sperm counts, Decreases in hemoglobin and hematocrit.
Monitor hemoglobin and hematocrit levels and liver trans aminases monthly, then every 3 months thereafter. Pregnancy test must be execersied each month.
Hepatic and renal adverse reactions of Bosentan may be worsen in geriatrics.